Phase II Study of Dasatinib in Previously Treated Patients With Advanced NSCLC

Summary

On this study patients will receive dasatinib, a targeted therapy, for advanced NSCLC that has progressed after previous therapy. Safety and response to dasatinib will be assessed. Fresh frozen tumor tissue must be available for genomics analysis prior to initiating dasatinib therapy. A biopsy must be obtained after any prior chemotherapy. If fresh frozen tumor tissue is not available, a biopsy will be required to participate in this trial.

Timeline

Start

2008-09

Primary completion

2013-06

Completion

2013-06

Outcome

Outcome not reported

Stopped (Enrollment): “Poor accrual”

Publications

• Background Downward J. Cancer biology: signatures guide drug choice. Nature. 2006 Jan 19;439(7074):274-5. doi: 10.1038/439274a. No abstract available.

Drugs

Indications